2026-W46 · Nov 9–Nov 15 · Company · Profile · published
Charles River Laboratories International, Inc. company profile · business segments · history · financial snapshot · S&P 500 rank #430 · Charles River公司業務歷史財務與標普500地位
SNAPSHOT
| Ticker | CRL |
| Company | Charles River Laboratories International, Inc. |
| GICS sector / industry | Health Care (XLV) / Life Sciences Tools & Services |
| S&P 500 rank (by weight) | #430 · 0.02% (Nov 4, 2026) |
| Sector rank | #51 of 60 in Health Care (Nov 4, 2026) |
| Headquarters | Wilmington, Massachusetts |
| Founded | 1947 |
| CEO | Birgit Girshick (President and CEO since May 5, 2026; succeeded James C. Foster, CEO throughout FY2025) |
| Employees | 19,700 (as reported; 10-K as-of year to confirm) |
| Market cap | $16.80B (Nov 4, 2026) |
| SEC filings | EDGAR — CIK 0001100682 |
WHAT IT DOES
Charles River Laboratories International, Inc. is a contract research organisation providing research models, discovery and safety-assessment services, and manufacturing testing that help pharmaceutical and biotechnology companies develop new medicines, headquartered in Wilmington, Massachusetts. Its laboratories test drugs for safety and efficacy before human trials.
Its one-line model: sell preclinical science as a service — bred research animals, safety studies and quality testing — to drug developers that outsource early development. Fiscal 2025 total revenue was $4.02B, but GAAP operating income collapsed to $25.2M and the company recorded a net loss available to common shareholders of $144.3M after large fourth-quarter charges including a $165.0M goodwill impairment.
The moat is validation and trust: safety data must satisfy regulators, and switching providers mid-programme is costly. Growth depends on biotech funding recovery, discovery demand and the reshaped portfolio after the February 2026 CDMO and discovery-services divestitures.
BUSINESS SEGMENTS
| Research Models and Services (RMS) | Purpose-bred rodents (rats and mice) and related research models and services. Fiscal 2025 revenue $846.1M (2024: $829.4M, +2.0%). |
| Discovery and Safety Assessment (DSA) | Early discovery, in vivo discovery, safety assessment and toxicology, pathology and bioanalysis. The largest segment, about 60% of revenue. Fiscal 2025 revenue $2.40B (2024: $2.45B, down 2.0%; down 2.6% organic). |
| Manufacturing Solutions (Manufacturing) | In vitro microbial and quality-control testing for sterile and non-sterile pharmaceuticals and consumer products, plus contract development and manufacturing (CDMO, divested February 2026). Fiscal 2025 revenue $766.4M. |
HISTORY
| Year | Milestone |
|---|---|
| 1947 | Dr. Henry Foster founds Charles River Breeding Laboratories in a second-floor Boston loft overlooking the Charles River, breeding Sprague-Dawley rats. |
| 1952 | Relocates to 60 acres of farmland in Wilmington, Massachusetts (eventual headquarters campus). |
| 1968 | First IPO on NASDAQ (offering size differs by source and is omitted here). |
| 1984 | Acquired by Bausch & Lomb. |
| 1999 | Management-led leveraged buyout from Bausch & Lomb; the holding company is renamed Charles River Laboratories International. |
| 2000 | Second IPO on the NYSE (CRL); raised $224M per encyclopaedia summary. |
COMPETITIVE POSITION
FINANCIAL SNAPSHOT
| Total revenue | $4.02B (FY2025 revenue) |
| Operating income | $25.2M (FY2025 operating income) |
| Net income | $(144.3)M (FY2025 net income) |
| Diluted EPS | $(2.91) (FY2025 diluted EPS) |
KEY RISKS
WHY IT MATTERS FOR THE S&P 500
Charles River is a small-weight health care constituent: rank #430 by weight at 0.02% as of Nov 4, 2026, and #51 in Health Care. As the leading independent preclinical research provider, it is a direct read on drug-development spending — the outsourced safety and discovery work behind new medicines.
SOURCES & METHODOLOGY
| Financials, segments, headquarters | Charles River Laboratories International, Inc. fiscal 2025 Form 10-K via SEC EDGAR and Q4/full-year 2025 results release (see Financial Snapshot note); headquarters, CEO and history via the Form 10-K and Wikipedia company profile |
| Index weight & ranks | Slickcharts S&P 500 weights, fetched Nov 4, 2026; sector membership per Wikipedia List of S&P 500 companies (GICS) |
| Market cap | $16.80B (Slickcharts, Nov 4, 2026) |
| Logo | SPXSet logo library, compiled from company official websites, filings, or Wikipedia; as company logos are dynamic corporate information, no 100% guarantee is made for the graphics. |
| Chart | SPXSet chart library, monthly bars, compiled from Yahoo public information. |
Source: Yahoo Finance monthly bars, split-adjusted · Data as of Sep 30, 2026 (last closed month) · SPXSet.com
FINANCIALS
公司快照
| 股票代號 | CRL |
| 公司 | Charles River Laboratories International, Inc.(Charles River) |
| GICS 板塊/行業 | 健康護理(XLV)/生命科學工具及服務 |
| 標普500排名(按權重) | #430 · 0.02%(Nov 4, 2026) |
| 板塊內排名 | 健康護理板塊 #51(共 60 家)(Nov 4, 2026) |
| 總部 | 美國麻薩諸塞州威爾明頓 |
| 成立 | 1947年 |
| 執行長 | Birgit Girshick(總裁兼執行長,自2026年5月5日起接任;James C. Foster 為2025財年執行長) |
| 員工 | 19,700人(據報道;10-K 截至年份待確認) |
| 市值 | $16.80B(Nov 4, 2026) |
| SEC 申報 | EDGAR — CIK 0001100682 |
業務概覽
Charles River Laboratories International, Inc. 是合約研究機構,提供研究模型、發現與安全評估服務及製造測試,協助製藥與生物科技公司開發新藥,總部位於麻薩諸塞州威爾明頓。實驗室在人體試驗前測試藥物的安全性與療效。
其一句話商業模式是:以服務形式銷售臨床前科學——繁殖研究動物、安全研究與質量測試——予外包早期開發的藥物開發商。2025 財年總收入 40.15 億美元,但 GAAP 營業利潤急跌至 0.25 億美元,歸屬普通股股東淨虧損 1.44 億美元,原因是第四季龐大費用,包括 1.65 億美元商譽減值。
護城河是驗證與信任:安全數據須令監管機構滿意,計劃中途轉換供應商成本高昂。增長依賴生物科技資金復甦、發現需求,以及 2026 年 2 月 CDMO 與發現服務剝離後的重塑組合。
業務板塊
| 研究模型及服務 | 專用繁殖齧齒動物(大鼠與小鼠)及相關研究模型與服務。2025 財年收入 8.461 億美元(2024 年:8.294 億美元,增長 2.0%)。 |
| 發現及安全評估 | 早期發現、體內發現、安全評估與毒理學、病理學及生物分析。最大板塊,約佔收入 60%。2025 財年收入 24.0 億美元(2024 年:24.5 億美元,下跌 2.0%;有機下跌 2.6%)。 |
| 製造方案 | 無菌與非無菌藥品及消費品的體外微生物與質量控制檢測,以及合約開發與製造(CDMO,2026 年 2 月剝離)。2025 財年收入 7.664 億美元。 |
歷史
| 年份 | 里程碑 |
|---|---|
| 1947 | Henry Foster 博士在俯瞰查爾斯河的波士頓二樓閣樓創立 Charles River Breeding Laboratories,繁殖 Sprague-Dawley 大鼠。 |
| 1952 | 遷往麻薩諸塞州威爾明頓 60 英畝農地(日後總部園區)。 |
| 1968 | 首次在納斯達克公開招股(發行規模因來源而異,此處從略)。 |
| 1984 | 由 Bausch & Lomb 收購。 |
| 1999 | 管理層主導槓桿收購,自 Bausch & Lomb 回購;控股公司更名為 Charles River Laboratories International。 |
| 2000 | 第二次在紐約證券交易所公開招股(CRL);按百科摘要集資 2.24 億美元。 |
競爭地位
財務快照
| 總收入 | 40.15 億美元(2025 財年收入) |
| 營業利潤 | 0.25 億美元(2025 財年營業利潤) |
| 淨利潤 | 虧損1.44億美元(2025 財年淨利潤) |
| 稀釋 EPS | 虧損2.91美元(2025 財年稀釋 EPS) |
主要風險
對標普500的重要性
Charles River 是權重較小的健康護理成分股:按權重排名 #430,權重 0.02%(以 2026 年 11 月 4 日為準),健康護理板塊內排名 #51。作為領先的獨立臨床前研究供應商,它是藥物開發開支的直接指標——新藥背後外包的安全與發現工作。
來源與方法
| 財務、板塊、總部 | Charles River Laboratories International, Inc. 2025 財年 Form 10-K 數據,經 SEC EDGAR 及 2025 年第四季/全年業績公佈(見財務快照附註);總部、執行長與歷史經 Form 10-K 及維基百科公司資料 |
| 指數權重與排名 | Slickcharts 標普 500 權重,Nov 4, 2026 抓取;板塊歸屬按維基百科標普 500 成分股名單(GICS) |
| 市值 | $16.80B(Slickcharts,Nov 4, 2026) |
| Logo | SPXSet logo 庫,整理自企業官方網站、文件或維基百科;由於是企業自身動態資訊,不對圖形做百分百保證。 |
| 股價圖 | SPXSet 圖表庫月線,整理自 Yahoo 公開資訊。 |
來源:Yahoo Finance 月線(經拆股調整)· 數據截至 2026 年 9 月 30 日(最後已收月份)· SPXSet.com
財報
SPXSet in-house research — market structure, options and volatility. Not investment advice.
SPXSet 站內獨立研究,聚焦 SPX 市場結構、期權與波動率;內容不構成投資建議。
Entered 2026-11-04 02:38 · updated 2026-11-14 23:14 · rev 6